Bristol-Myers Squibb Company Ce (CELG-RI) P/E Ratio History
Historical price-to-earnings valuation from 2022 to 2026
Loading P/E history...
CELG-RI Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Bristol-Myers Squibb Company Ce (CELG-RI) trades at a price-to-earnings ratio of 0.0x, with a stock price of $0.11 and trailing twelve-month earnings per share of $3.55.
The current P/E is 16% above its 5-year average of 0.0x. Over the past five years, CELG-RI's P/E has ranged from a low of 0.0x to a high of 0.0x, placing the current valuation at the 64th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, CELG-RI trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, CELG-RI trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CELG-RI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CELG-RI P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $115B | 16.3 | - | +178% | |
| $277B | 15.4Lowest | 0.73 | +8% | |
| $151B | 19.5 | - | -4% | |
| $283B | 27.9 | 1.28 | +191% | |
| $921B | 42.5 | 1.47 | +96% | |
| $358B | 85.5 | - | -1% | |
| $166B | 19.8 | 0.15Best | +1684%Best | |
| $28B | 21.7 | - | -21% | |
| $74B | 17.1 | 2.70 | +8% | |
| $108B | 27.7 | 3.35 | +837% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CELG-RI Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $0.12 | $3.56 | 0.0x | +24% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $0.06 | $3.45 | 0.0x | -31% |
| FY2025 Q3 | $0.03 | $2.96 | 0.0x | -57% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $0.03 | $2.48 | 0.0x | -62% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $0.05 | $2.67 | 0.0x | -29% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $0.09 | $3.86 | 0.0x | -12% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $0.10 | $3.94 | 0.0x | -9% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $0.11 | $3.76 | 0.0x | +11% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $0.13 | $3.43 | 0.0x | +39% |
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $0.12 | $2.95 | 0.0x | +52% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $0.14 | $3.07 | 0.0x | +73% |
Average P/E for displayed period: 0.0x
See CELG-RI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CELG-RI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CELG-RI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCELG-RI — Frequently Asked Questions
Quick answers to the most common questions about buying CELG-RI stock.
Is CELG-RI stock overvalued or undervalued?
CELG-RI current P/E: 0.0x. 5-year average P/E: 0.0x. Percentile: 64th.
How does CELG-RI's valuation compare to peers?
Bristol-Myers Squibb Company Ce P/E of 0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is CELG-RI's PEG ratio?
CELG-RI PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2022-2026.